Literature DB >> 7512363

Cytogenetic deletion maps of hematologic neoplasms: circumstantial evidence for tumor suppressor loci.

B Johansson1, F Mertens, F Mitelman.   

Abstract

Research in oncogenetics has led to the identification of two major classes of tumor-associated genes, oncogenes and tumor suppressor genes. In a wide variety of solid tumor types, mutations of both groups of genes have been implicated in the tumorigenic process. In hematologic neoplasms, on the other hand, most attention has focused on illegitimate activation of oncogenes, e.g., deregulation leading to disturbed transcriptional activity and structural rearrangements resulting in hybrid genes. Whether loss or mutational inactivation of tumor suppressor genes also plays an essential role in the genesis of tumors of the hematopoietic system has received less attention. Because such inactivation can be the result of karyotypically detectable loss of chromosomal material, cytogenetic studies may prove helpful in pinpointing genomic sites that harbor tumor suppressor genes. The present study is based on a total of 12,473 cytogenetically abnormal hematologic neoplasms reported in the literature to date. Among these, we selected the 6,422 cases with sole clonal chromosomal abnormalities in order to include only aberrations of importance in the genesis, rather than in the progression, of these neoplasms. All tumors with monosomies or structural abnormalities resulting in loss of chromosomal material were compiled, and for every such structural aberration, i.e., deletion, unbalanced translocation, isochromosome, and ring chromosome, the chromosome bands lost were ascertained. This cytogenetic deletion mapping revealed that the most commonly lost chromosomes were Y and 7 in acute myeloid leukemia (AML), myelodysplastic syndromes (MDS), and chronic myeloproliferative disorders (MPD); X, Y, 7, 20, and 21 in acute lymphocytic leukemia (ALL); X, Y, and 17 in chronic lymphoproliferative disorders (LPD); and X and Y in non-Hodgkin's lymphoma (NHL). Chromosome segments/bands lost due to unbalanced structural abnormalities in at least 5% of the cases were 5q13-33, 7q22-36, 9q13-31, 11q23-25, 12p12-13, 17p11-13, and 20q11-13 in AML; 5q13-35 and 20q11-13 in MDS; 5q22-23, 7q22, 13q12-22, 17p11-13, and 20q11-13 in MPD; 6q15-27, 9p11-24, 12p12-13, and 19p13 in ALL; 6q16-27, 11q21-25, 13q13-14, and 14q32 in LPD; and 6q21-27, 11q13-25, and 14q24-32 in NHL. Based on these findings, three conclusions can be drawn. First, there is no good correspondence between total and partial monosomies, the only exception being -7 and 7q-, both of which are common in myeloid neoplasms. This indicates different pathogenetic effects of total and partial losses.(ABSTRACT TRUNCATED AT 400 WORDS)

Entities:  

Mesh:

Year:  1993        PMID: 7512363     DOI: 10.1002/gcc.2870080402

Source DB:  PubMed          Journal:  Genes Chromosomes Cancer        ISSN: 1045-2257            Impact factor:   5.006


  16 in total

Review 1.  Cell death controlling complexes and their potential therapeutic role.

Authors:  Alexey V Zamaraev; Gelina S Kopeina; Boris Zhivotovsky; Inna N Lavrik
Journal:  Cell Mol Life Sci       Date:  2014-10-17       Impact factor: 9.261

2.  Molecular cytogenetic delineation of a novel critical genomic region in chromosome bands 11q22.3-923.1 in lymphoproliferative disorders.

Authors:  S Stilgenbauer; P Liebisch; M R James; M Schröder; B Schlegelberger; K Fischer; M Bentz; P Lichter; H Döhner
Journal:  Proc Natl Acad Sci U S A       Date:  1996-10-15       Impact factor: 11.205

3.  Molecular delineation of the smallest commonly deleted region of chromosome 5 in malignant myeloid diseases to 1-1.5 Mb and preparation of a PAC-based physical map.

Authors:  N Zhao; A Stoffel; P W Wang; J D Eisenbart; R Espinosa; R A Larson; M M Le Beau
Journal:  Proc Natl Acad Sci U S A       Date:  1997-06-24       Impact factor: 11.205

4.  Secondary acute myeloid leukaemia with 7q- complicating azathioprine treatment for rheumatoid arthritis.

Authors:  C C Mok; Y L Kwong; C S Lau
Journal:  Ann Rheum Dis       Date:  1995-02       Impact factor: 19.103

Review 5.  The search for a gene involved in the determination of limited duplicative capacity in human cells.

Authors:  E Calef; A Scotto d'Abusco; E Bianchi; S Gargano; A Fruscalzo
Journal:  Genetica       Date:  1994       Impact factor: 1.082

6.  Isochromosome 9q as a sole anomaly in an Omani boy with acute lymphoblastic leukaemia.

Authors:  Udayakumar Muthappa Achandira; Anil V Pathare; Salam Al Kindi; David Dennison; Said Al Yahyaee
Journal:  BMJ Case Rep       Date:  2009-04-28

Review 7.  Ataxia telangiectasia gene mutations in leukaemia and lymphoma.

Authors:  J Boultwood
Journal:  J Clin Pathol       Date:  2001-07       Impact factor: 3.411

8.  Accurate molecular classification of cancer using simple rules.

Authors:  Xiaosheng Wang; Osamu Gotoh
Journal:  BMC Med Genomics       Date:  2009-10-30       Impact factor: 3.063

9.  Fusion of the TEL gene on 12p13 to the AML1 gene on 21q22 in acute lymphoblastic leukemia.

Authors:  T R Golub; G F Barker; S K Bohlander; S W Hiebert; D C Ward; P Bray-Ward; E Morgan; S C Raimondi; J D Rowley; D G Gilliland
Journal:  Proc Natl Acad Sci U S A       Date:  1995-05-23       Impact factor: 11.205

Review 10.  Caspase 2 in apoptosis, the DNA damage response and tumour suppression: enigma no more?

Authors:  Sharad Kumar
Journal:  Nat Rev Cancer       Date:  2009-11-05       Impact factor: 60.716

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.